Get to know our clinical trials
Clinical trial of advanced or metastatic triple-negative breast cancer with adoptive therapy of PD1-positive tumor infiltrating lymphocytes.
THE TILS001 STUDY AIMS TO STUDY A NEW TYPE OF THERAPY CALLED ADOPTIVE CELL THERAPY BY INFUSION OF TUMOR INFILTRATING LYMPHOCYTES WHOSE CELLS EXPRESS A PROTEIN CALLED PD1). THE ACRONYM FOR THIS TREATMENT IS TILS PD1 WHICH STANDS FOR: TUMOR-INFILTRATING LYMPHOCYTES EXPRESSING PROGRAMMED CELL DEATH PROTEIN 1. T LYMPHOCYTES ARE PART OF THE BODY'S IMMUNE SYSTEM AND HELP FIGHT INFECTIONS AND OTHER DISEASES; INSIDE TUMORS THERE IS USUALLY A TYPE OF NATURALLY INFILTRATING T LYMPHOCYTES, HENCE THEIR NAME INFILTRATING (SO-CALLED TILS). THE AIM OF THIS STUDY IS TO EXTRACT TILS FROM THE PATIENT'S TUMOR, SELECT THOSE THAT WILL ATTACK THE TUMOR IN A MORE SPECIFIC WAY AND INCREASE THEIR NUMBER IN A LABORATORY IN ORDER TO SUBSEQUENTLY ADMINISTER THEM.
- Code EudraCT: 2020-003638-19
- Protocol number: TILS001
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.